First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics

NCT07169318 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

78

Enrollment

NIH

Sponsor class

Conditions

Influenza

Interventions

OTHER: Placebo for VNT-101
DRUG: VNT-101

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)